Lam Research Could Swing $28.6 Billion After Earnings
Discover 9 stocks with the biggest options-implied earnings moves, led by Spotify at 9.31%, as investors prepare for key quarterly results.
Stocks · News reference
Barclays Initiates Coverage On Intuitive Surgical with Overweight Rating, Announces Price Target of $485
Barclays analyst Christopher Pasquale initiates coverage on Intuitive Surgical (NASDAQ:ISRG) with a Overweight rating and announces Price Target of $485.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.
Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for CRBG, MTN, CRM and FSLR, while cutting targets for PVLA, SPOT and AMZN; CRM and FSLR were upgraded.
BTIG Maintains Buy on Intuitive Surgical, Lowers Price Target to $454
BTIG analyst Ryan Zimmerman maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and lowers the price target from $469 to $454.